KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Assets: 2017-2025

Historic Current Assets for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $6.6 billion.

  • Moderna's Current Assets fell 31.74% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year decrease of 31.74%. This contributed to the annual value of $8.1 billion for FY2024, which is 21.56% down from last year.
  • As of Q3 2025, Moderna's Current Assets stood at $6.6 billion, which was up 6.92% from $6.2 billion recorded in Q2 2025.
  • Moderna's Current Assets' 5-year high stood at $16.4 billion during Q1 2022, with a 5-year trough of $6.2 billion in Q2 2025.
  • For the 3-year period, Moderna's Current Assets averaged around $9.1 billion, with its median value being $9.7 billion (2024).
  • As far as peak fluctuations go, Moderna's Current Assets soared by 836.29% in 2021, and later plummeted by 36.12% in 2025.
  • Quarterly analysis of 5 years shows Moderna's Current Assets stood at $16.1 billion in 2021, then declined by 16.43% to $13.4 billion in 2022, then decreased by 23.13% to $10.3 billion in 2023, then declined by 21.56% to $8.1 billion in 2024, then plummeted by 31.74% to $6.6 billion in 2025.
  • Its Current Assets stands at $6.6 billion for Q3 2025, versus $6.2 billion for Q2 2025 and $6.8 billion for Q1 2025.